News & Events about Uipath Inc.
UiPath Inc. (NYSE:PATH Get Rating) has earned a consensus recommendation of Moderate Buy from the nineteen analysts that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 ...
UiPath Inc. (NYSE:PATH Get Rating) has received a consensus recommendation of Moderate Buy from the nineteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and seven have ...
Thinking about buying stock in Anavex Life Sciences, RA Medical Systems, Samsara, UiPath, or Smartsheet? Thinking about buying stock in Anavex Life Sciences, RA Medical Systems, Samsara, UiPath, or Smartsheet? PR Newswire NEW YORK, Dec. 2, 2022 NEW YORK, Dec. 2, 2022 /PRNewswire...
Business Wire
2 months ago
UiPath (NYSE: PATH), a leading enterprise automation software company, today announced an enhanced partnership with Neostella, a UiPath Diamond partner which specializes in automation, business consulting, and implementation services, to bring managed services to the midmarket business segment...
Shares of UiPath Inc. (NYSE:PATH Get Rating) have earned a consensus rating of Moderate Buy from the twenty brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy ...